Loading organizations...
ActiTrexx GmbH is a clinical-stage biotechnology company based in Mainz, Germany, that develops cellular therapies utilizing activated regulatory T cells to treat transplant rejection and autoimmune disorders. The enterprise primarily focuses on its lead candidate, ATreg, which is designed to prevent severe graft-versus-host disease in leukemia patients undergoing stem cell transplantation. Operating with a team of 11 employees, the firm functions both as a therapeutic developer and a contract development and manufacturing organization to support broader European market coverage. The biotechnology startup has secured €3.5 million in Series A funding backed by institutional investors including High-Tech Gründerfonds, LBBW Venture Capital, and Investitions- und Strukturbank Rheinland-Pfalz. ActiTrexx GmbH was officially founded in 2020 as a commercial spin-off from the University Medical Center Mainz by Andrea Tüttenberg, Helmut Jonuleit, Franz-Joseph Schneider, and Michael Kring.
ActiTrexx GmbH has raised $4.2M across 1 funding round.
ActiTrexx GmbH has raised $4.2M in total across 1 funding round.
ActiTrexx GmbH has raised $4.2M across 1 funding round. Most recently, it raised $4.2M Series A in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 2, 2021 | $4.2M Series A | Stefanie Wojciech | High Tech Grunderfonds, Investitions UND Strukturbank Rheinland Pfalz, Mediventures | Announced |
ActiTrexx GmbH has raised $4.2M in total across 1 funding round.
ActiTrexx GmbH's investors include Stefanie Wojciech, High-Tech Grunderfonds, Investitions- und Strukturbank Rheinland-Pfalz, MediVentures.
